Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae289 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Jeffrey Weber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Grossman School of Medicine, NYU Langone, New York, NY 10016, United States. Hauptthemen laut MEDLINE: Melanoma, Imidazoles, Proto-Oncogene Proteins B-raf, Oximes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Background
In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat resection following relapse on/after 1L adjuvant CPI. Patients and methods This was a retrospective review of BRAF V600-mutated resected stage III/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant CPI immunotherapy, relapsed locoregionally/distantly, were again resected to no evidence of disease, and received dabrafenib/trametinib (dab/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS) from initiation of 2L adjuvant dab/tram (RFS-2), analyzed via Kaplan-Meier methods.
Results
Thirty-eight patients were included (median age 50 years, 63% male, 87% stage III, median follow-up 19 months from 2L dab/tram initiation). Median dab/tram duration was 10.1 months (range: 1 day–22.7 months), with half discontinuing due to progression or adverse events. Median (95% CI) RFS-2 was 18.9 (14.9–28.1) months, with 91%, 81%, and 58% remaining relapse-free at 6, 12, and 18 months, respectively. Most patients remained distant metastasis-free at 6, 12, and 18 months (97%, 85%, and 71%, respectively). Two patients were deceased at the last follow-up, with 97% alive at 18 months.
Conclusions
Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab/tram initiation, with only 2 deaths observed. Dab/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Grossman School of Medicine, NYU Langone, New York, NY 10016, United States.
- Department of Medicine, NYU Grossman School of Medicine, NYU Langone, New York, NY 10016, United States.
- Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN 55905, United States.
- Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, United States.
- The Angeles Clinic and Research Institute, Cedars Sinai, Los Angeles, CA 90025, United States.
- Center for Melanoma, Massachusetts General Hospital, Boston, MA 02114, United States.
ORCID-Profile: Siddharth Karanth
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Weber, J., Haque, W., Markovic, S. N., Salama, A. K. S., Mehmi, I., Sullivan, R. J., Najjar, Y. G., van Akkooi, A. C. J., Menzies, A. M., Long, G. V., Taylor, A. M., Haanen, J., Zijlker, L. P., Davis, K. L., Karanth, S., Norton, D., & Connolly, L. (2025). Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae289
Vancouver
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, et al. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae289
BibTeX
@article{Weber2025,
author = {Weber, Jeffrey and Haque, Waqas and Markovic, Svetomir N and Salama, April K S and Mehmi, Inderjit and Sullivan, Ryan J and Najjar, Yana G and van Akkooi, Alexander C J and Menzies, Alexander M and Long, Georgina V and Taylor, Amelia M and Haanen, John and Zijlker, Lisanne P and Davis, Keith L and Karanth, Siddharth and Norton, Deborah and Connolly, Lucy},
title = {Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae289}
}
EUVIMED